Beijing Meikang Geno-immune Biotechnology Co., Ltd. specializes in immune cell R&D, together with technology development, technical consulting, and the translation of research achievements in the field of gene therapy. The company maintains close technical collaboration with the Shenzhen Geno-immune Medical Institute. Built on a high-performance lentiviral vector platform and proprietary patented technologies, it develops the core vector materials required for CAR-T cell manufacturing, establishing clear technological advantages in vector production capacity and cost control.

Together, the two organizations pursue the clinical translation of fourth-generation CAR-T cell therapy, with a pipeline covering hematologic cancers and solid tumors, and sustained clinical research partnerships with medical institutions across China. The company's R&D portfolio reserves more than 150 CAR-T cell target development programs, with technical validation across multiple tumor indications and a growing body of clinical experience in leukemia, lymphoma, and other diseases.

The pipeline also extends to gene therapy research for inherited diseases. Supported by high-titer lentiviral vector processes, the company explores approaches to restoring gene function through intrathecal administration and intravenous vector infusion.

Meikang Geno-immune will continue to deepen its commitment to the cell and gene therapy field, accelerate the clinical translation of frontier immunotherapies, and work with clinical partners to advance innovation across the cell therapy industry.